natgillin/translations-raw huggingface dataset:
In a clinical study of pregnant women with mechanical prosthetic heart valves given enoxaparin sodium (100 IU/kg (1 mg/kg ) twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and foetal death.
V klinični študiji nosečnic z mehaničnimi protetičnimi srčnimi zaklopkami, ki so dobivale natrijev enoksaparinat (100 i.e./kg (1 mg/kg) dvakrat na dan) za zmanjšanje tveganja za trombembolijo, so se pri 2 od 8 žensk pojavili krvni strdki, ki so povzročili zamašitev zaklopke ter smrt matere in ploda.
In these patients, careful clinical monitoring is advised, and biological monitoring by antiXa activity measurement might be considered (see sections 4.2 and 5.2).
Pri teh bolnikih je priporočljiv natančen klinični nadzor in v poštev pride biološko spremljanje z meritvijo aktivnosti anti-Xa (glejte poglavji 4.2 in 5.2).
Supplied in packs of 2 or 10 pre-filled syringes.
Pakirano v škatlah po 2 ali 10 napolnjenih injekcijskih brizg.
• Skin irritation (local irritation).
• Draženje kože (lokalno draženje).
Heparin aPTT Adjusted IV Therapy n (%)
Heparinglede na aPTČ prilagojeno intravensko zdravljenje n (%)
• An increase in the number of eosinophils in your blood.
• Večje število eozinofilcev v krvi.
Besides the anticoagulant effects of enoxaparin sodium, there was no evidence of adverse effects at 15 mg/kg/day in the 13-week SC toxicity studies both in rats and dogs and at 10 mg/kg/day in the 26-week SC and IV toxicity studies both in rats, and monkeys.
Poleg antikoagulantnega učinka natrijevega enoksaparinata niso ugotovili znakov neželenih učinkov ne v 13-tedenski študiji toksičnosti subkutane uporabe 15 mg/kg/dan pri podganah in psih ne v 26-tedenskih študiji toksičnosti subkutane in intravenske uporabe 10 mg/kg/dan pri podganah in opicah.
Paediatric population The safety and efficacy of enoxaparin sodium in paediatric population have not been established.
Pediatrična populacija Varnost in učinkovitost natrijevega enoksaparinata pri pediatrični populaciji nista ugotovljeni.
For dosage in elderly patients with impaired kidney function, see below “renal impairment” and section 4.4.
Za odmerjanje pri starejših bolnikih z okvarjenim delovanjem ledvic glejte "Okvara ledvic", spodaj, in poglavje 4.4.
• Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
• Profilakso venske trombembolične bolezni pri nekirurških bolnikih z akutno boleznijo (npr. z akutnim srčnim popuščanjem, respiratorno insuficienco, hudimi okužbami ali revmatskimi boleznimi) in zmanjšano mobilnostjo, ki imajo povečano tveganje za vensko trombembolijo.
9) Drop the used syringe with its protective sleeve into the sharps bin provided.
9) Uporabljene injekcijske brizge z zaščitnim tulcem odložite v zabojnik za ostre predmete.
Do not try to inject yourself if you have not been trained how to do so.
Injiciranja ne izvajajte sami, vas tega ni nihče naučil.
When non-weight adjusted dosing was administered, it was found after a single-SC 4,000 IU (40 mg) dose, that anti-Xa exposure is 52% higher in low-weight women (<45 kg) and 27% higher in low-weight men (<57 kg) when compared to normal weight control subjects (see section 4.4).
Če so uporabili odmerjanje, ki ni bilo korigirano za telesno maso, so po enkratnem subkutanem odmerku 4.000 i.e. (40 mg) ugotovili izpostavljenost anti-Xa, ki je bila pri ženskah z majhno telesno maso (< 45 kg) 52 % večja in pri moških z majhno telesno maso (< 57 kg) 27 % večja kot pri kontrolnih osebah z normalno telesno maso (glejte poglavje 4.4).
• Medicinal products increasing potassium levels:
• Zdravila, ki zvišujejo koncentracijo kalija:
Therefore, careful clinical monitoring is advised in these patients (see section 5.2).
Zato je treba te bolnike priporočljivo klinično nadzorovati (glejte poglavje 5.2).
Plasma anti-IIa activity after SC administration is approximately ten-fold lower than anti-Xa activity.
Plazemska aktivnost anti-IIa je po subkutani uporabi približno desetkrat manjša kot aktivnost anti-Xa.
If an epidural anaesthesia is planned, it is recommended to withdraw enoxaparin sodium treatment before (see section 4.4).
Če je načrtovana epiduralna anestezija, je priporočljivo pred tem prenehati zdravljenje z natrijevim enoksaparinatom (glejte poglavje 4.4).
Should the physician decide to administer anticoagulation in the context of epidural or spinal anaesthesia/analgesia or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), bowel and/or bladder dysfunction.
Če se zdravnik odloči, da bo uporabil antikoagulantno zdravljenje v primeru epiduralne/spinalne anestezije/analgezije ali lumbalne punkcije, sta potrebna skrajna pozornost in pogost nadzor, da bi odkrili znake in simptome nevrološke okvare, npr. bolečino v srednji črti hrbta, senzorične ali motorične izpade (omrtvičenost ali šibkost spodnjih udov) ter moteno delovanje črevesa in/ali sečnega mehurja.
The site of the procedure should be observed for signs of bleeding or hematoma formation.
Mesto posega je treba opazovati, da bi odkrili znake krvavitve ali nastanka hematoma.
In comparison with heparin, enoxaparin sodium significantly reduced the combined incidence of angina pectoris, myocardial infarction and death, with a decrease of 19.8 to 16.6% (relative risk reduction of 16.2%) on day 14.
Natrijev enoksaparinat je v primerjavi s heparinom značilno zmanjšal skupno incidenco angine pektoris, miokardnega infarkta in smrti, z zmanjšanjem z 19,8 na 16,6 % (relativno zmanjšanje za 16,2 %) 14. dan.
Plasma potassium should be monitored regularly especially in patients at risk.
Bolnikom s tveganjem je treba redno kontrolirati kalij v plazmi.
Thorinane can be used to:
Zdravilo Thorinane se uporablja za:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Če ste noseči, domnevate, da ste noseči ali nameravate zanositi, se posvetujte z zdravnikom, preden vzamete to zdravilo.
This is because it needs to be given as an injection.
To zdravilo je namreč treba injicirati.
If you stop using Thorinane
Če ste prenehali uporabljati zdravilo Thorinane
Similar to the first study the incidence of VTE during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo for both total VTE (enoxaparin sodium 21 [16%] versus placebo 45 [34.4%]; p=0.001) and proximal DVT (enoxaparin sodium 8 [6.1%] versus placebo 28 [21.4%]; p=<0.001).
Podobno kot v prvi študiji je bila incidenca VTE med podaljšano profilakso značilno manjša z natrijevim enoksaparinatom kot s placebom, in sicer tako za vse VTE (natrijev enoksaparinat 21 [16 %] in placebo 45 [34,4 %], p = 0,001) kot za GVT (natrijev enoksaparinat 8 [6,1 %] in placebo 28 [21,4 %], p =< 0,001.
Thorinane should not be used interchangeably with other medicines belonging to the group of low molecular weight heparins.
Zdravila Thorinane se ne sme uporabljati medsebojno zamenljivo z drugimi zdravili iz skupine nizkomolekularnih heparinov.
Appropriate antiplatelet therapy such as oral acetylsalicylic acid (75 mg to 325 mg once daily) should be administered concomitantly unless contraindicated.
Sočasno je treba uporabiti ustrezno antiagregacijsko zdravljenje, na primer peroralno acetilsalicilno kislino (od 75 do 325 mg enkrat na dan), če ni kontraindicirano.
• Bruising or pain at the injection site.
• Podplutba ali bolečina na mestu injiciranja
Throw away the cap.
Pokrovček zavrzite.
After you have had a heart attack
Po srčnem infarktu
Placebo once a day SC n (%)
Placebo enkrat na dan subkutano n (%)
Confounding factors, including underlying disease and insufficient clinical data, limit the evaluation of these cases.
Možnost za oceno teh primerov omejujejo moteči dejavniki, med drugim osnovna bolezen in nezadostni klinični podatki.
Do not use this medicine if you notice any visible change in the appearance of the solution.
Zdravila ne uporabite, če opazite spremembe v videzu raztopine.
In moderate risk patients, enoxaparin sodium treatment should be maintained for a minimal period of 710 days whatever the recovery status (e.g. mobility).
Pri bolnikih z zmernim tveganjem je treba zdravljenje z natrijevim enoksaparinatom nadaljevati vsaj še 7 do 10 dni, ne glede na stanje okrevanja (npr. mobilnost).
Packs of 2 and 10 pre-filled syringes.
Pakiranje po 2 in 10 napolnjenih injekcijskih brizg.
• Pregnant women with mechanical prosthetic heart valves
• Nosečnice z mehaničnimi protetičnimi srčnimi zaklopkami
Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients Individual thromboembolic risk for patients can be estimated using validated risk stratification model.
Profilaksa venske trombembolične bolezni pri kirurških bolnikih z zmernim ali velikim tveganjem Tveganje za trombembolijo je mogoče pri posameznem bolniku oceniti z validiranim modelom stratifikacije tveganja.
Beyond its anti-Xa/IIa activity, further antithrombotic and anti-inflammatory properties of enoxaparin have been identified in healthy subjects and patients as well as in non-clinical models.
Poleg enoksaparinovega delovanja anti-Xa/IIa so pri zdravih osebah, bolnikih in v nekliničnih modelih ugotovili še dodatne antitrombotične in protivnetne lastnosti enoksaparina.
Prophylaxis of venous thromboembolic disease in medical patients with an acute illness expected to induce limitation of mobility
Profilaksa venske trombembolične bolezni pri nekirurških bolnikih z akutno boleznijo, zaradi katere je mogoče pričakovati omejeno mobilnost
No data are available in patients using enoxaparin sodium for prophylaxis or treatment and during haemodialysis sessions.
Podatkov o bolnikih, ki bi uporabljali natrijev enoksaparinat za profilakso ali zdravljenje in med hemodializami, ni.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
Če imate kakšna dodatna vprašanja o uporabi tega zdravila, se obrnite na zdravnika, farmacevta ali medicinsko sestro.
Administration in spinal/epidural anaesthesia or lumbar puncture Should the physician decide to administer anticoagulation in the context of epidural or spinal anaesthesia/analgesia or lumbar puncture, careful neurological monitoring is recommended due to the risk of neuraxial haematomas (see section 4.4).
Uporaba v primeru spinalne/epiduralne anestezije ali lumbalne punkcije Če se zdravnik odloči, da bo uporabil antikoagulantno zdravljenje v okviru epiduralne ali spinalne anestezije/analgezije ali lumbalne punkcije, je zaradi tveganja za nevraksialne hematome priporočljiv skrben nevrološki nadzor (glejte poglavje 4.4).
Heparins can suppress adrenal secretion of aldosterone leading to hyperkalaemia (see section 4.8), particularly in patients such as those with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, taking medicinal products known to increase potassium (see section 4.5).
Heparini lahko zavrejo izločanje aldosterona iz nadledvičnih žlez in lahko zaradi tega povzročijo hiperkaliemijo (glejte poglavje 4.8), zlasti pri bolnikih s sladkorno boleznijo, kronično odpovedjo ledvic ali obstoječo metabolično acidozo in pri uporabnikih zdravil, ki zvišujejo kalij (glejte poglavje 4.5).
A linear relationship between anti-Xa plasma clearance and creatinine clearance at steady-state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function.
V stanju dinamičnega ravnovesja so ugotovili linearno povezanost med plazemskim očistkom anti-Xa in očistkom kreatinina, kar kaže na zmanjšan očistek natrijevega enoksparinata pri bolnikih z zmanjšanim delovanjem ledvic.
Diluted medicinal product with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose 8 hours
Zdravilo, razredčeno z 0,9-odstotno raztopino natrijevega klorida (9 mg/ml) za injiciranje ali 5-odstotno glukozo
The treatment benefits of enoxaparin sodium, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35 percent reduction in the relative risk of myocardial re-infarction, as compared with treatment with unfractionated heparin (p<0.001).
Koristi zdravljenja z natrijevim enoksaparinatom, ki so se kazale s številnimi izidi učinkovitosti, so se pojavile po 48 urah: ob tem času je bilo relativno tveganje za ponovni miokardni infarkt 35 odstotkov manjše kot z nefrakcioniranim heparinom (p < 0,001).
These included 1,776 for prophylaxis of deep vein thrombosis following orthopaedic or abdominal surgery in patients at risk for thromboembolic complications, 1,169 for prophylaxis of deep vein thrombosis in acutely ill medical patients with severely restricted mobility, 559 for treatment of DVT with or without PE, 1,578 for treatment of unstable angina and non-Q-wave myocardial infarction and 10,176 for treatment of acute STEMI.
To je obsegalo 1.776 primerov za profilakso globoke venske tromboze po ortopedski ali trebušni operaciji pri bolnikih s tveganjem za trombembolične zaplete, 1.169 za profilakso globoke venske tromboze pri akutno bolnih nekirurških bolnikih z zelo omejeno mobilnostjo, 559 za zdravljenje GVT s PE ali brez nje, 1.578 za zdravljenje nestabilne angine pektoris in miokardnega infarkta brez zobca Q ter 10.176 za zdravljenje akutnega STEMI.
To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, NSTEMI and acute STEMI, adhere precisely to the intervals recommended between enoxaparin sodium injection doses.
Za zmanjšanje nevarnost krvavitve po žilnih posegih med zdravljenjem nestabilne angine pektoris, NSTEMI in akutnega STEMI, se morate natanko držati priporočenih presledkov med injiciranjem odmerkov natrijevega enoksaparinata.
Indication Prophylaxis of venous thromboembolic disease
Profilaksa venske trombembolične bolezni
Elderly patients (especially patients eighty years of age and older) may be at an increased risk for bleeding complications with the therapeutic dosage ranges.
V območju terapevtskih odmerkov pa lahko starejše bolnike (zlasti bolnike, stare osemdeset let in več) bolj ogrožajo krvavitveni zapleti.
• Rare: Cases of immuno-allergic thrombocytopenia with thrombosis; in some of them thrombosis was complicated by organ infarction or limb ischaemia (see section 4.4).
• Redki: Primeri imuno-alergijske trombocitopenije s trombozo; v nekaterih primerih se je kot zaplet tromboze pojavil infarkt organov ali ishemija udov (glejte poglavje 4.4).
For patients with a high risk of haemorrhage, the dose should be reduced to 50 IU/kg (0.5 mg/kg) for double vascular access or 75 IU/kg (0.75 mg/kg) for single vascular access.
Bolnikom, ki imajo veliko tveganje za krvavitev, je treba odmerek zmanjšati na 50 i.e./kg (0,5 mg/kg) v primeru dvojnega žilnega dostopa ali na 75 i.e./kg (0,75 mg/kg) v primeru enojnega žilnega dostopa.
There was a higher incidence of gastrointestinal bleeding in the enoxaparin sodium group (0.5%) versus the heparin group (0.1%), while the incidence of intracranial haemorrhage was similar in both groups (0.8% with enoxaparin sodium versus 0.7% with heparin).
Incidenca gastrointestinalnih krvavitev je bila v skupini z natrijevim enoksaparinatom večja (0,5 %) kot v skupini s heparinom (0,1 %), incidenca intrakranialnih krvavitev pa je bila v obeh skupinah podobna (0,8 % z natrijevim enoksaparinatom in 0,7 % s heparinom).
Your doctor will request you perform blood tests called INR and tell you when to start Thorinane accordingly.
Zdravnik vam bo naročil, da opravite preiskavo krvi, imenovano INR, in vam bo glede na to povedal, kdaj naj nehate uporabljati zdravilo Thorinane.
In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see section 4.4 and 'Description of selected adverse reactions' below).
V kliničnih študijah so bili najpogosteje zabeleženi neželeni učinki krvavitve, trombocitopenija in trombocitoza (glejte poglavje 4.4 in "Opis izbranih neželenih učinkov", spodaj).
• - If you are allergic to enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6).
• - Če ste alergični na natrijev enoksaparinat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
• Rare: Eosinophilia*
• Redki: Eozinofilija*
• Acute coronary syndrome: - Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
• Akutni koronarni sindrom: - Zdravljenje nestabilne angine pektoris in miokardnega infarkta brez dviga spojnice ST (NSTEMI) v kombinaciji s peroralno acetilsalicilno kislino.
For patients currently receiving a VKA, the VKA should be discontinued and the first dose of enoxaparin sodium should be given when the INR has dropped below the therapeutic range.
Bolnikom, ki trenutno prejemajo VKA, je treba VKA ukiniti in jim prvi odmerek natrijevega enoksaparinata dati, ko se vrednost INR zniža pod terapevtsko območje.
For continuous techniques, a similar delay of 24 hours should be observed before removing the
V primeru kontinuiranih tehnik je potreben podoben odlog 24 ur pred odstranitvijo katetra.
Switch between enoxaparin sodium and oral anticoagulants
Prehod med natrijevim enoksaparinatom in peroralnimi antikoagulansi
In patients with severe renal impairment (creatinine clearance <30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated SC 4,000 IU (40 mg) once daily doses (see sections 4.2 and 4.4).
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) je AUC v stanju dinamičnega ravnovesja bistveno večja, povprečno za 65 % po večkratni subkutani uporabi odmerkov 4.000 i.e. (40 mg) enkrat na dan (glejte poglavji 4.2 in 4.4).
Absorption The absolute bioavailability of enoxaparin sodium after SC injection, based on anti-Xa activity, is close to
Absolutna biološka uporabnost natrijevega enoksaparinata po subkutani injekciji je na podlagi aktivnosti anti-Xa skoraj 100 %.
The use of enoxaparin sodium for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied.
Uporaba natrijevega enoksaparinata za tromboprofilakso pri nosečnicah z mehaničnimi protetičnimi srčnimi zaklopkami ni ustrezno raziskana.
In patients with renal impairment, there is an increase in exposure of enoxaparin sodium which increases the risk of bleeding.
Bolniki z okvaro ledvic so bolj izpostavljeni natrijevemu enoksaparinatu in to povečuje tveganje za krvavitev.
• Aspirin (also known as acetylsalicylic acid or ASA), clopidogrel or other medicines used to stop blood clots from forming (see also in section 3, “Changing of anticoagulant medicine”)
• Acetilsalicilno kislino, klopidogrel ali druga zdravila, ki se uporabljajo za preprečevanje nastajanja krvnih strdkov (glejte tudi "Menjava antikoagulantnih zdravil" v poglavju 3).
- Changing from Thorinane to treatment with direct oral anticoagulant Stop taking Thorinane.
- Prehod z zdravila Thorinane na zdravljenje z neposrednim peroralnim antikoagulansom Nehajte jemati zdravilo Thorinane.
There are no clinical data for enoxaparin sodium in fertility.
Kliničnih podatkov o plodnosti v zvezi z natrijevim enoksaparinatom ni.
• If you are allergic to enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6).
• Če ste alergični na natrijev enoksaparinat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
For IV injection, either the multidose vial or prefilled syringe can be used.
Za intravensko injiciranje je mogoče uporabiti ali večodmerno vialo ali napolnjeno injekcijsko brizgo.
Signs of an allergic reaction include: rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.
Med znaki alergijske reakcije so: izpuščaj, težave s požiranjem ali dihanjem, oteklost ustnic, obraza, žrela ali jezika.
- Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
- Zdravljenje akutnega miokardnega infarkta z dvigom spojnice ST (STEMI), vključno z bolniki, ki bodo zdravljeni konzervativno ali s poznejšo perkutano koronarno intervencijo (PKI).
Studies conducted in pregnant rats and rabbits at SC doses of enoxaparin sodium up to 30 mg/kg/day did not reveal any evidence of teratogenic effects or foetotoxicity.
Študije odmerkov do 30 mg/kg/dan natrijevega enoksaparinata, izvedene pri brejih podganah in kuncih, niso pokazale teratogenih učinkov ali fetotoksičnosti.
Preoperative initiation (2 hours before surgery) of enoxaparin sodium 2,000 IU (20 mg) was proven effective and safe in moderate risk surgery.
Dokazano je, da je predoperacijska uvedba (2 uri pred operacijo) 2.000 i.e. natrijevega enoksaparinata (20 mg) pri operacijah z zmernim tveganjem učinkovita in varna.
Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as:
Tako kot druge antikoagulanse je treba tudi natrijev enoksaparinat previdno uporabljati pri stanjih, povezanih z večjo možnostjo za krvavitve; takšna so npr.:
PC: SN: NN:
SN: {številka}
Very common: Haemorrhage α
Zelo pogosti: Krvavitev α
The incidence of DVT during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo, no PE was reported.
Incidenca GVT je bila med podaljšano profilakso z natrijevim enoksaparinatom značilno manjša kot s placebom in zabeležili niso nobenega primera PE.
To reduce the potential risk of bleeding associated with the concurrent use of enoxaparin sodium and epidural or spinal anaesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of enoxaparin sodium (see section 5.2).
Da bi zmanjšali tveganje za krvavitve, povezano s sočasno uporabo natrijevega enoksaparinata in epiduralne oz. spinalne anestezije/analgezije ali spinalne punkcije, je treba upoštevati farmakokinetične značilnosti natrijevega enoksaparinata (glejte poglavje 5.2).
You may have a blood test before you start using this medicine and at intervals while you are using it; this is to check the level of the clotting cells (platelets) and potassium in your blood.
Pred začetkom uporabe tega zdravila in v presledkih med zdravljenjem boste morda opravili preiskavo krvi, s katero bo zdravnik kontroliral število trombocitov (krvnih ploščic) in kalija v krvi.
Common: Thrombocytosis β
Pogosti: Trombocitoza β
• Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for treatment in the previous 24 hours (see section 4.4).
• Spinalno ali epiduralno anestezijo ali lokoregionalno anestezijo v primeru uporabe natrijevega enoksaparinata v predhodnih 24 urah (glejte poglavje 4.4).
• Monitoring of platelet counts
• Nadziranje števila trombocitov
There was a significant treatment benefit of enoxaparin sodium, as compared with unfractionated heparin, in patients who underwent percutaneous coronary intervention within 30 days after randomization (23 percent reduction in relative risk) or who were treated medically (15 percent reduction in relative risk, p=0.27 for interaction).
Natrijev enoksaparinat je v primerjavi z nefrakcioniranim heparinom pokazal značilno terapevtsko korist pri bolnikih, ki so imeli perkutano koronarno intervencijo v 30 dneh po randomizaciji (23-odstotno relativno zmanjšanje tveganja) ali so bili zdravljeni konzervativno (15-odstotno relativno zmanjšanje tveganja, p = 0,27 za interakcijo).
The use of enoxaparin sodium has not been adequately studied for thromboprophylaxis in patients with mechanical prosthetic heart valves.
Uporaba natrijevega enoksaparinata ni ustrezno raziskana za tromboprofilakso pri bolnikih z mehaničnimi protetičnimi srčnimi zaklopkami.
If a manual compression method is used, sheath should be removed 6 hours after the last IV/SC enoxaparin sodium injection.
Če uporabite ročno kompresijo, morate ovojnico odstraniti 6 ur po zadnji intravenski/subkutani injekciji natrijevega enoksaparinata.